Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

eiletoclax

An orally bioavailable inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon oral administration, eiletoclax targets and binds to the P2 pocket of Bcl-2, thereby inhibiting the activity of Bcl-2. This restores apoptotic processes in tumor cells. Bcl-2 is overexpressed in many cancers and plays an important role in the negative regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:ZE 50-0134
ZE-50-0134
ZE50-0134
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search